Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2010 | Original Paper

Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Authors: Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun-ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Ichiro Yasuda, Naoki Katsumura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2010

Abstract

Introduction

We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL.

Patients

Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years.

Results

The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen.

Conclusion

We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.

A predictive model for aggressive non-Hodgkin’s lymphoma (1993) The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 329:987–994CrossRef

Aoki S, Tsukada N, Nomoto N, Maruyama S, Takahashi M, Moriyama Y, Shibata A, Aizawa Y (1998) Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 17:465–470PubMed

Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M et al (1994) P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin’s lymphoma (NHL). Ann Oncol 5:895–900PubMed

Bertini M, Freilone R, Vitolo U, Botto B, Ciotti R, Cinieri S, Di Nota A, Di Vito F, Levis A, Orsucci L, Pini M, Rota-Scalabrini D, Todeschini G, Resegotti L (1996) The treatment of elderly patients with aggressive non-Hodgkin’s lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 22:483–493. doi:10.3109/10428199609054787 CrossRefPubMed

Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31:1860–1861PubMed

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMed

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242. doi:10.1056/NEJMoa011795 CrossRefPubMed

Cox DR (1972) Regression models and life-tables (with discussions). J Roy Statist Soc Ser B Methodol 34:187–220

Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 21:3041–3050. doi:10.1200/JCO.2003.01.076 CrossRefPubMed

Fisher RI, Shah P (2003) Current trends in large cell lymphoma. Leukemia 17:1948–1960. doi:10.1038/sj.leu.2403096 CrossRefPubMed

Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006. doi:10.1056/NEJM199304083281404 CrossRefPubMed

Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 109–236

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868 CrossRef

Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin’s lymphoma in the elderly. Am J Clin Oncol 13(Suppl 1):S15–S19. doi:10.1097/00000421-199012001-00005 PubMedCrossRef

Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268. doi:10.1002/mpo.2950220410 CrossRefPubMed

Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, Mizoguchi H, Shibata A, Saito H, Matsuda T, Masaoka T, Harada M, Niho Y, Takaku F (2005) Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 81:246–254. doi:10.1532/IJH97.03147 CrossRefPubMed

Niitsu N, Umeda M (1997) THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin’s lymphoma in elderly patients: a prospective study. Leukemia 11:1817–1820. doi:10.1038/sj.leu.2400001 CrossRefPubMed

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641. doi:10.1182/blood-2003-06-2095 CrossRefPubMed

Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E (2008a) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435–444. doi:10.1016/S1470-2045(08)70078-0 CrossRefPubMed

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008b) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–116. doi:10.1016/S1470-2045(08)70002-0 CrossRefPubMed

Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi:10.1034/j.1600-0609.2002.01654.x CrossRefPubMed

Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079–1085PubMed

Takagi T, Oguro M (1987) (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154. doi:10.1007/BF00253970 CrossRefPubMed

Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi:10.1007/s00432-003-0508-9 CrossRefPubMed

Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114. doi:10.1002/hon.815 CrossRefPubMed

Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32:1082–1084

Title: Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma
Authors: Takeshi Hara
Hisashi Tsurumi
Naoe Goto
Jun-ichi Kitagawa
Nobuhiro Kanemura
Takeshi Yoshikawa
Senji Kasahara
Hideko Goto
Kenji Fukuno
Toshiki Yamada
Michio Sawada
Ichiro Yasuda
Naoki Katsumura
Takeshi Takahashi
Tsuyoshi Takami
Hisataka Moriwaki
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0637-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Patients

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma

Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines

The prognostic role of phospho-Src family kinase analysis in tongue cancer

Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2

Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer

Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials